# Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer

**Authors:** Eudald Felip, Edurne Garcia‐Vidal, Sara Cabrero‐de las Heras, Adrià Bernat‐Peguera, Beatriz Cirauqui, Milana Bergamino, Vanesa Quiroga, Iris Teruel, Angelica Ferrando‐Díez, Anna Pous, Assumpció Lopez‐Paradís, Laia Boronat, Marga Romeo, Ricard Mesía, Pedro Luis Fernandez, Bonaventura Clotet, Eva Riveira‐Muñoz, Anna Martínez‐Cardús, Ester Ballana, Mireia Margelí

PMC · DOI: 10.1002/ctm2.70426 · Clinical and Translational Medicine · 2025-08-07

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** breast cancer (MESH:D001943), HR (MESH:D002303)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12331873/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12331873/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12331873/full.md

---
Source: https://tomesphere.com/paper/PMC12331873